Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results

Context Therapeutics (NASDAQ:CNTX) issued its earnings results on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01, FiscalAI reports.

Context Therapeutics Stock Down 6.6%

Context Therapeutics stock traded down $0.01 during mid-day trading on Tuesday, hitting $0.19. 719,001 shares of the company’s stock traded hands, compared to its average volume of 1,736,806. Context Therapeutics has a one year low of $0.18 and a one year high of $3.62. The firm has a 50 day moving average price of $0.30 and a 200 day moving average price of $1.41. The company has a market cap of $17.18 million, a PE ratio of -0.39 and a beta of 1.77.

Wall Street Analysts Forecast Growth

CNTX has been the subject of several recent research reports. Lifesci Capital lowered Context Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Weiss Ratings upgraded Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 15th. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Zacks Research downgraded Context Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 12th. Finally, Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $6.40.

About Context Therapeutics

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.